Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166070 | 0.85 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL20111131 | 0.84 | NR1H2 (0.53) | NR1H2NAMPTEPHX1SMN1; SMN2USP2 | |
| SCHEMBL21166088 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL21166089 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL11998894 | 0.79 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL2937689 | 0.79 | ATM (0.34) | NR1H2ATM | |
| SCHEMBL19686899 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL17664667 | 0.78 | POLB (0.45) | NR1H2PDE4BATMSMN1; SMN2 | |
| SCHEMBL20026858 | 0.78 | ATM (0.41) | NR1H2ATM | |
| SCHEMBL21165814 | 0.78 | NAMPT (0.34) | NR1H2ATMNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CHRNB2 504/4885CHRNA4 365/4885CHRNB4 542/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CHRNB2 504/4885CHRNA4 365/4885CHRNB4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.